Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
22 results
  • Colorectal Cancer

24-643          Phase II

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

  • Lung Cancer, Pancreatic Cancer, Melanoma, Colorectal Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations

  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Lung Cancer, Colorectal Cancer, Pancreatic Cancer

25-022          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors

  • Gastric (Stomach) Cancer, Colorectal Cancer, Lung Cancer

23-340          Phase II

A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors

  • Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Prostate Cancer, Ovarian Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Colorectal Cancer, Lung Cancer

21-398          Phase I

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

24-649          Phase I

A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors

  • Colorectal Cancer, Lung Cancer, Breast Cancer

24-514          Phase I

A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)

  • Sarcoma, Prostate Cancer, Pancreatic Cancer, Lung Cancer, Kidney Cancer, Gastric (Stomach) Cancer, Endometrial Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

Showing 1 - 10 of 22 results